ARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally. On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $5.00 This would be a 581% gain from the current level. Looking...
This trade is not actionable without volume confirmation, wedge breakout, and ofc a SET SL AND TP ALSO looking at GAP fill over $2.00+
Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is only...
Ardelyx shares are trading higher after Ladenburg Thalmann upgraded the stock from Neutral to Buy and announced a $6 price target. Also, Citigroup maintained a Buy rating and raised its price target from $7 to $13. Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and...
Reason for buy 1. price is all-time low 2. Super big volume came in 3. strong daily up candle. Happy trade
Ardelyx, Inc. ARDX yesterday had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is...
Following the negative news that sent this stock into an 82% tailspin there is no viable buy signal aside from a simple long-term play. Trend is continuing downward slowly. Has yet to find a solid support zone. By way of Analyst Consensus, upside is above 100% but may take 12-months to materialize. By way of previous share price average, upside is close to...
The current falling wedge in 1H has absolute bottom of 1.69$. If the bulls manage to break this wedge things can get interesting.
The FDA is unlikely to approve Ardelyx`s drug for dialysis patients. Ardelyx received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought. The most likely target is the 1.6usd support line from which it can bounce up.
This is not financial advice. This thesis is exclusively based on technical analysis without catalyst. Bullish trend expected to continue and hit new highs as long as volume is high. Stop loss set at closest support.
Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates ARDX D1::BEST level to BUY 100% gains (SWING)(STOCKS) IMPORTANT...
This is not financial advise you do what is make you feeling comfort ARDX will easy hit Short Term : TG1 $7 Long term : TG2 $7.57 TG3 $8.05 if you like me advise follow me thanks for your support
This is not financial advise you do what is make you feeling comfort ARDX will easy hit Short Term : T1 $7 Long term : T2 $7.57 T3 $8.05 GOOD LUCK
This is not financial advise you do what is make you feeling comfort ARDX will easy hit Short Term : T1 $7 Long term : T2 $7.57 T3 $8.05 if you like me advise follow me thanks for your support
This is not financial advise you do what is make you feeling comfort ARDX will easy hit Short Term : TG1 $7 Long term : TG2 $7.57 TG3 $8.05 if you like me advise follow me thanks for your support